Edition:
India

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

86.64CHF
2:12pm IST
Change (% chg)

CHF-0.38 (-0.44%)
Prev Close
CHF87.02
Open
CHF87.00
Day's High
CHF87.12
Day's Low
CHF86.60
Volume
268,973
Avg. Vol
4,567,900
52-wk High
CHF92.80
52-wk Low
CHF71.84

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.05
Market Cap(Mil.): CHF219,900.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.27

Financials

  NOVN.S Industry Sector
P/E (TTM): 31.37 31.13 34.39
EPS (TTM): 2.68 -- --
ROI: 6.14 15.55 14.96
ROE: 9.19 16.92 16.52

J&J says its psoriasis drug superior to Novartis treatment in study

Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.

13 Dec 2018

UPDATE 2-J&J says its psoriasis drug superior to Novartis treatment in study

Dec 12 Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.

13 Dec 2018

J&J says its psoriasis drug superior to Novartis' in study

Dec 12 Johnson & Johnson said on Wednesday its drug Tremfya was more effective than a rival medicine from Novartis AG, and met the main goal of a late-stage study in adults with moderate to severe plaque psoriasis.

12 Dec 2018

Swiss stocks - Factors to watch on Dec. 11

ZURICH/BERLIN, Dec 11 The Swiss blue-chip SMI was seen opening 1.0 percent higher at 8,634 points on Tuesday, according to premarket indications by bank Julius Baer .

11 Dec 2018

Novartis to launch Adamis' EpiPen rival in U.S. next year

Dec 6 Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

07 Dec 2018

J&J unit to pay $360 million to U.S. to resolve charity kickback probe

BOSTON A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday.

07 Dec 2018

UPDATE 3-J&J unit to pay $360 mln to U.S. to resolve charity kickback probe

BOSTON, Dec 6 A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday.

07 Dec 2018

J&J unit to pay $360 mln to U.S. to resolve charity kickback probe

BOSTON, Dec 6 A unit of Johnson & Johnson has agreed to pay the U.S. government $360 million to resolve an investigation into its financial support of charities that help Medicare patients cover out-of-pocket drug costs, the U.S. Justice Department said on Thursday.

06 Dec 2018

Novartis's new treatment for hives outperforms Xolair in trials

ZURICH Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.

04 Dec 2018

Novartis's new treatment for hives outperforms Xolair in trials

ZURICH Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.

04 Dec 2018

Earnings vs. Estimates